PDCD1 and hepatocellular carcinoma: A Chinese retrospective study described 60 patients with advanced HCC (55% with macrovascular invasion, 27% with extrahepatic disease) treated with lenvatinib combined with anti-PD-1 antibodies, showing an ORR of 33%.